Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Summary

The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.

Timeline

Start

2021-02-19

Primary completion

2023-03-16

Completion

2023-09-15

Publications

• Corley MJ, Pang APS, Kitch DW, Kantor A, Sattler F, Belaunzaran-Zamudio PF, Brown TT, Landay A, Lake JE, Erlandson KM. Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study. NPJ Aging. 2026 Apr 21. doi: 10.1038/s41514-026-00383-9. Online ahead of print.
• Erlandson KM, Kitch DW, Kantor A, Belaunzaran-Zamudio PF, Brown TT, Fichtenbaum CJ, Heath SL, Sattler FR, Lake JE. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV. Clin Infect Dis. 2026 Mar 17;82(3):e544-e548. doi: 10.1093/cid/ciaf652.
• Corley M, Pang A, Kitch D, Kantor A, Sattler F, Belaunzaran-Zamudio P, Brown T, Landay A, Lake J, Erlandson K. Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study. Res Sq [Preprint]. 2025 Oct 1:rs.3.rs-7697256. doi: 10.21203/rs.3.rs-7697256/v1.
• Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, Belaunzaran-Zamudio PF, Brown TT, Corey K, Landay AL, Avihingsanon A, Sattler FR, Erlandson KM. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clin Infect Dis. 2025 Feb 24;80(2):389-396. doi: 10.1093/cid/ciae384.

Drugs

Indications